CYP19A1 and cancer: Specifically, cancers such as breast (selective estrogen receptor modulators, aromatase inhibitors, CDK4/6 inhibitors), prostate (androgen biosynthesis inhibitors), and lung (TKIs) have highly effective oral therapies.